Combination Pravastatin and Valsartan Treatment Has Additive Beneficial Effects to Simultaneously Improve Both Metabolic and Cardiovascular Phenotypes Beyond That of Monotherapy With Either Drug in Patients With Primary Hypercholesterolemia

  1. Michael J. Quon5
  1. 1Cardiology, Gachon University Gil Medical Center, Incheon, Korea
  2. 2Division of Endocrinology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
  3. 3Department of Statistics, University of Seoul, Seoul, Korea
  4. 4Cardiovascular Medicine, Hokko Memorial Clinic, Sapporo, Japan
  5. 5Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
  1. Corresponding author: Kwang Kon Koh, kwangk{at}gilhospital.com.

Abstract

Statin and angiotensin II type 1 receptor blocker therapy improves endothelial dysfunction using distinct mechanisms. We evaluated simultaneous vascular and metabolic responses to pravastatin and valsartan therapy, alone or in combination, in hypercholesterolemic patients. Forty-eight hypercholesterolemic patients (23 had metabolic syndrome) were given pravastatin 40 mg and placebo, pravastatin 40 mg and valsartan 160 mg, or valsartan 160 mg and placebo daily during each 2-month treatment period in a randomized, single-blind, placebo-controlled, crossover trial with three treatment arms and two washout periods (each 2 months). Brachial artery flow-mediated dilation and C-reactive protein improved to a greater extent with combined therapy compared with either monotherapy. Importantly, we also observed simultaneous improvement in metabolic phenotypes, with all three treatments causing increased plasma adiponectin levels, reduced fasting insulin levels, and increased insulin sensitivity relative to baseline measurements. For the first time in a statin combination trial, pravastatin combined with valsartan therapy increased plasma adiponectin, lowered fasting insulin levels, and improved insulin sensitivity in an additive manner when compared with monotherapy alone. In contrast to other statins, hydrophilic pavastatin may be combined with other drugs to safely reach lipid target levels while simultaneously improving the metabolic and cardiovascular phenotype of patients at high risk.

  • Received April 10, 2013.
  • Accepted July 6, 2013.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

| Table of Contents

This Article

  1. Diabetes vol. 62 no. 10 3547-3552
  1. All Versions of this Article:
    1. db13-0566v1
    2. 62/10/3547 most recent